@drjonesdc

2 posts audited · 11 claims analysed

Instagram profile

Science evidence grade

64%Moderate evidence grade

Based on 11 claims across 2 audits

SupportedOverstatedMisleadingNo Evidence

7

Supported

64%

0

Overstated

0%

0

Misleading

0%

4

No Evidence

36%

Share this evidence grade

Claim-level evidence grades — not a character judgment. Methodology · Right of reply · Leaderboards

What @drjonesdc claims actually are

We separate claims into three buckets: backed by evidence, factually incorrect, and grey — like animal-only findings sold as human fact (e.g. BPC-157 “fixes Achilles” from rat studies).

Evidence-based

64%

7 claims

Claims that align with published human or clinical evidence at the stated strength.

Ex: “Semaglutide can reduce body weight in adults with obesity” — supported by large RCTs.

Factually incorrect

0%

0 claims

Claims that conflict with the evidence, invent certainty, or omit critical safety/context in a misleading way.

Ex: “Peptides have no side effects” — contradicts known adverse-event profiles.

Grey / overstated

36%

4 claims

Plausible direction but wrong certainty — animal-only data sold as human fact, dose/effect overstated, or no adequate published support yet.

Ex: “BPC-157 fixes Achilles tears” — often rests on rodent tendon models, not proven human Achilles repair trials.

Evidence mix

Share of audited claims in each bucket

Loading…
BackedIncorrectGrey

Verdict detail

Grey splits into overstated (wrong certainty) vs no published support

Loading…

Claims over time

Stacked by bucket as audits land — plus the running evidence grade

Loading…

Gold line = running science evidence grade (Supported + ½ Overstated ÷ total claims).

Audit history(2 posts)

Post thumbnail
✅ Supported
Posted Jul 24, 2026·4 months ago·View post

“MOTS-c: 10 mg Once A Week #healthoptimization #metabolicflexibility”

All six claims are supported by available evidence. Claims 1–3 (MOTS-c activates AMPK; AMPK is an energy sensor; AMPK activation is MOTS-c's primary goal) are supported by the canonical Lee et al. 2015 identification study and PeptIQ's internal curated knowledge base, which explicitly positions AMPK activation as central to MOTS-c's mechanism. Claims 4–6 (training, fasting, and chronic AMPK activation → mTOR inhibition) are supported by registered human clinical trials and well-established preclinical literature documenting these pathways. No contradictions were identified. The creator did not cite specific studies, but the conceptual framework is consistent with peer-reviewed science across multiple evidence tiers.

Post thumbnail
✅ Supported
Posted Sep 24, 2025·about 1 year ago·View post

“BPC-157 Protocol Revealed #peptides #bpc157 #peptidetherapy”

Claims 1–4 present specific dosing protocols, combinations, and treatment sequences for BPC-157 and TB500 in acute and chronic injuries that have no support in published human clinical trials, registered clinical studies, or PubMed literature. These are internally consistent protocols but lack any empirical backing. Claim 5 (that chronic injuries involve cell migration) is conceptually sound and reflects established wound healing physiology. The creator has not cited specific studies for any of these claims, and no relevant human evidence was found to validate the proposed treatment regimens.

Audit another post from @drjonesdc

Paste their social post link to add a new audit

New audit